FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
Filed with ASX · · 2 pages · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Argenica Receives $2.09m R&D Tax Incentive Cash Rebate
- ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
- Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
- Ethics Approval Received for Phase 2 Trial
- Grant Awarded To Develop Additional Administration Route
Later from Argenica Therapeutics
- Appointment of Non-Executive Chair
- Phase 2 Manufacturing Completed & Trial Update
- FDA Grants Rare Pediatric Disease Designation For HIE
- First Patient Dosed in Phase 2 Stroke Trial of ARG-007
- Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics